ClinicalTrials.Veeva

Menu

Safety and Efficacy of Valsartan vs Atenolol and Hydrochlorothiazide Combination on Blood Flow in Hypertensive Patients

Novartis logo

Novartis

Status and phase

Completed
Phase 3

Conditions

Hypertension

Treatments

Drug: Valsartan
Drug: Atenolol
Drug: Hydrochlorothiazide (HCTZ))

Study type

Interventional

Funder types

Industry

Identifiers

NCT00396656
CVAH631BDE06

Details and patient eligibility

About

This study evaluated the effect of valsartan on small vessel blood flow in patients with mild-to-moderate hypertension in direct comparison to atenolol and hydrochlorothiazide.

Enrollment

30 patients

Sex

All

Ages

40 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Caucasian; male or female outpatients and age between 40-65 years of age, inclusive.
  • At Visit 2 all patients must have a mean sitting diastolic blood pressure (msSBP) of ≥ 90 mmHg and < 110 mmHg.

Exclusion criteria

  • If a single reading for arterial hypertension in msSBP > 180 mmHg or msDBP > 110 mmHg at any visit after randomization.
  • Inability to discontinue all prior antihypertensive medications safely for a period of 2 weeks prior to randomization.
  • Known history of hypotensive symptoms or orthostatic hypotension.
  • Concomitant use of statins or statin intake during the four weeks prior to Visit 1.
  • Known Keith-Wagener grade III or IV hypertensive retinopathy.
  • A history of heart failure (NYHA II-IV).

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

None (Open label)

30 participants in 2 patient groups

Valsartan followed by atenolol + hydrochlorothiazide (HCTZ)
Experimental group
Description:
After a 2-week washout period, patients were treated with valsartan for 20 weeks followed by one week in which it was tapered off. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. The valsartan dose was then tapered off to 80 mg for one week. Patients took valsartan film coated tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning.
Treatment:
Drug: Atenolol
Drug: Hydrochlorothiazide (HCTZ))
Drug: Valsartan
Atenolol + hydrochlorothiazide (HCTZ) followed by valsartan
Experimental group
Description:
After a 2-week washout period, patients were treated with atenolol plus HCTZ for 20 weeks followed by one week in which atenolol was tapered off and HCTZ was discontinued. Patients received atenolol 100 mg for 20 weeks. Patients took atenolol tablets orally once a day (od) in the morning. Patients received HCTZ 12.5 mg for 4 weeks starting at the beginning of the 5th week and then received 25 mg for 12 weeks. Patients took HCTZ tablets orally once a day (od) in the morning. After a second 2-week washout period, patients were treated with valsartan for 20 weeks. Patients received valsartan 160 mg for 4 weeks, followed by valsartan 320 mg for 16 weeks. Patients took valsartan film coated tablets orally once a day (od) in the morning.
Treatment:
Drug: Atenolol
Drug: Hydrochlorothiazide (HCTZ))
Drug: Valsartan

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems